Core Viewpoint - Metsera, Inc. has issued a statement in response to litigation filed by Pfizer, asserting disagreement with the allegations and indicating plans to address them in court [1]. Company Response to Litigation - Metsera disagrees with the allegations made in Pfizer's complaint and will respond in the Delaware Court of Chancery [1]. Proposed Acquisition Details - The statement includes forward-looking information regarding Pfizer's proposed acquisition of Metsera, highlighting potential benefits and risks associated with the acquisition process [1]. - The acquisition is subject to various risks, including litigation expenses, potential damages, and the impact on Metsera's business and stock price [1]. Regulatory and Approval Considerations - The completion of the proposed acquisition depends on satisfying conditions such as obtaining necessary regulatory approvals and the requisite vote from Metsera's stockholders [1]. - There is a possibility that the acquisition may not close or that competing offers may arise [1]. Market and Business Impact - The announcement of the litigation and the proposed acquisition could negatively affect the market price of both Pfizer's and Metsera's common stock [1]. - The integration of businesses post-acquisition may face challenges, impacting operational relationships and the ability to retain qualified personnel [1]. Pipeline Products and Clinical Trials - The statement discusses Metsera's pipeline products and the associated risks, including the potential for adverse events and the uncertainties inherent in clinical trials [1]. - Metsera's reliance on third parties for clinical trials and product manufacturing is also noted as a risk factor [1].

Accessibility StatementSkip Navigation THOUSAND OAKS, Calif., Oct. 31, 2025 /PRNewswire/ --Â Amgen (NASDAQ:AMGN) today announced that its Board of Directors declared a $2.38 per share dividend for the fourth quarter of 2025. The dividend will be paid on December 12, 2025, to all stockholders of record as of the close of business on November 21, 2025. About AmgenAmgen discovers, develops, manufactures and delivers innovative medicines to help millions of patients in their fight against some of the world's to ...

Accessibility StatementSkip Navigation GAITHERSBURG, Md., Oct. 30, 2025 /PRNewswire/ --Â Novavax, Inc. (Nasdaq: NVAX) today announced it will report its third quarter 2025 financial results and operational highlights at 8:30 a.m. Eastern Time (ET) on Thursday, November 6, 2025. Details of the event and replay are as follows: Conference call details:Â Date:Â Â Â Â Â Â Â Â Â Â Â Â Â Â Â Â November 6, 2025 Time:Â Â Â Â Â Â Â Â Â Â Â Â Â Â Â 8:30 a.m. ET URL to register phone:Â Â Register Here Dial-in number:Â ...

Accessibility StatementSkip Navigation LUND, Sweden, Oct. 29, 2025 /PRNewswire/ -- Hansa Biopharma AB, "Hansa" (Nasdaq Stockholm: HNSA) today announced that it will host a virtual event featuring two distinguished transplant surgeons; Professor Robert Montgomery from NYU Langone Transplant Institute and Professor Matthew Cooper from the Medical College of Wisconsin, to provide deeper insights into the medical journey of highly sensitized patients awaiting a kidney transplant and share perspectives on the cl ...

Accessibility StatementSkip Navigation Indivior to Report Third Quarter 2025 Financial Results and Host Webcast on October 30th Indivior PLC (Nasdaq: INDV) today announced that it will report its third quarter 2025 financial results on Thursday, October 30, 2025, at 7:00 a.m.... WANT YOUR COMPANY'S NEWS FEATURED ON PRNEWSWIRE.COM? 440k+Newsrooms &Influencers 9k+Digital MediaOutlets 270k+JournalistsOpted In GET STARTED Also from this source RICHMOND, Va., Oct. 28, 2025 /PRNewswire/ -- Indivior PLC (NASDAQ ...

Accessibility StatementSkip Navigation PLYMOUTH MEETING, Pa., Oct. 27, 2025 /PRNewswire/ -- INOVIO (NASDAQ:INO), a biotechnology company focused on developing and commercializing DNA medicines to help treat and protect people from HPV-associated diseases, cancers, and infectious diseases, today announced that its third quarter 2025 financial results will be released after the market close on November 10, 2025. Following the release, INOVIO will host a live conference call and webcast at 4:30 p.m. ET to dis ...

Core Insights - Ascletis Pharma Inc. is presenting multiple posters on its obesity treatment programs, including ASC30, at ObesityWeek 2025 in Atlanta, Georgia, highlighting advancements in its obesity portfolio [1][2]. Group 1: Product Details - ASC30 is an investigational GLP-1 receptor biased small molecule agonist, designed for both oral and subcutaneous administration, with patent protection until 2044 [3]. - ASC31 is a novel peptide agonist targeting GLP-1R and GIPR, showing favorable pharmacokinetics and efficacy in diet-induced obese mice [4]. - ASC47 is a once-monthly subcutaneous injected small molecule agonist targeting thyroid hormone receptor beta, designed for adipose tissue targeting [5]. Group 2: Event Information - ObesityWeek 2025 will take place from November 4 to 7, 2025, featuring the latest developments in obesity research and treatment [7]. - Presentations at the event include a full analysis of a 28-day study of ASC30 and comparisons of ASC31 and ASC47 against existing treatments [2]. Group 3: Company Overview - Ascletis Pharma Inc. focuses on developing best-in-class therapeutics for metabolic diseases, utilizing proprietary technologies for drug discovery [8].

Core Insights - Theravance Biopharma, Inc. will report its Q3 2025 financial results and provide a business update on November 10, 2025, after market close [1] - A conference call and webcast will be held on the same day at 5:00 pm EST [2] Company Overview - Theravance Biopharma focuses on delivering impactful medicines, leveraging decades of expertise [3] - The company has developed YUPELRI (revefenacin), an FDA-approved inhalation solution for chronic obstructive pulmonary disease (COPD) [3] - Ampreloxetine, a late-stage investigational drug, is being developed for neurogenic orthostatic hypotension in patients with Multiple System Atrophy, potentially becoming a first-in-class therapy [3]

Core Insights - Actinium Pharmaceuticals, Inc. has presented promising preclinical data for ATNM-400, a first-in-class antibody radioconjugate targeting a novel, non-PSMA antigen, demonstrating superior efficacy in prostate cancer treatment compared to existing therapies [1][2][3] Prostate Cancer Treatment Insights - ATNM-400 shows robust tumor control and extended survival in enzalutamide-resistant prostate cancer models, achieving complete tumor regression in 40% of treated animals [4][5] - The therapy demonstrated five times more durable anti-tumor efficacy compared to enzalutamide alone, extending tumor control to 100 days versus approximately 20 days with enzalutamide [4][11] - In models resistant to 177Lu-PSMA-617, ATNM-400 exhibited approximately two times longer overall survival and maintained potent therapeutic activity independent of PSMA expression levels [6][11] Mechanism and Differentiation - ATNM-400 targets a distinct, non-PSMA antigen associated with treatment resistance, providing a mechanistically differentiated approach to alpha-radiotherapy [8][13] - The combination of ATNM-400 with enzalutamide resulted in synergistic effects, enhancing treatment responses and overcoming resistance [9][16] Market Context and Unmet Needs - Prostate cancer remains a significant health issue, with approximately 1.5 million new cases globally and over 313,000 expected in the U.S. in 2025, highlighting the need for effective treatments [14] - A substantial portion of metastatic castration-resistant prostate cancer (mCRPC) patients do not respond to PSMA-targeted therapies, with 25%-30% having low or no detectable PSMA [7][14] Future Directions - Actinium Pharmaceuticals is advancing ATNM-400 into non-small cell lung cancer (NSCLC) treatment, where it has shown potential to overcome resistance to osimertinib [9][13] - The company envisions multiple clinical applications for ATNM-400, including monotherapy, combination therapy with ARPI, and sequential therapy for patients relapsing after standard treatments [12][15]

Core Insights - Caris Life Sciences will report its third quarter 2025 financial results on November 5, 2025, and will host a conference call at 3:30 p.m. CT [1] - The company is recognized as a leading, patient-centric, next-generation AI TechBio firm and a pioneer in precision medicine [2] Company Overview - Caris Life Sciences specializes in developing and commercializing innovative healthcare solutions through comprehensive molecular profiling and advanced AI and machine learning algorithms [2] - The company has established a large-scale, multimodal clinico-genomic database to analyze the molecular complexity of diseases, enhancing precision medicine diagnostic solutions [2] - Founded with the vision to improve the human condition through precision medicine, Caris is headquartered in Irving, Texas, with additional offices in Phoenix, New York, Cambridge (MA), Tokyo, Japan, and Basel, Switzerland [2]